Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study

Abstract

The MAGE-A3 expression rate showed that a promising proportion of operable patients with early-stage non-small cell lung cancers are possible candidates for trials investigating adjuvant therapy with MAGE-A3 immunization. Currently, a phase two trial of adjuvant MAGE-A3 vaccination is in progress.

Lung Cancer Immunotherapy

“…40 In a clinical trial, 41 nine NSCLC patients were vaccinated with the protein; 3 developed antibody responses. Seven of 8 patients who received MAGE-3 combined with adjuvant ASO2B generated antibodies against MAGE-3.…”

Screening of Differentially Expressed Genes among Various TNM Stages of Lung Adenocarcinoma by Genomewide Gene Expression Profile Analysis

“…It is a promising target for anticancer immunotherapy because it is exclusively presented on the cell surface of cancer cells and might be associated with an aggressive cancer phenotype. Sienel (2004) compared the expression of MAGE-A3 in Stage I and Stage II NSCLCs, and found that in comparison to Stage I, the rate of MAGE-A3 positive tumors was significantly increased in Stage II, in agreement with its possible role in the tumor metastasis. Consistent with what reported, we found that the expression of MAGE-A3 mRNA was significantly increased in lung adenocarcinomas at stage II and IIIA compared with stage I. MAGE-A3 may also be a candidate target for the immunotherapy of lung adenocarcinoma.…”

Targeting the immune system for management of NSCLC: the revival?

“…It is recognized by cytotoxic T cells in the presence of the human leukocyte antigen-A1 molecule. In NSCLC, MAGE-A3 expression has been reported in approximately 24-50 % of tumors [39][40][41], with expression more frequently occurring in histology of squamous cell, rather than adenocarcinoma [40][41][42]. Like MUC-1, expression of MAGE-A3 is associated with poor prognosis in NSCLC [43].…”